The result of this phase II study showed promising treatment outcomes, as the administration of intranasal insulin improved delayed memory ability, Dementia Severity Rating Scale (DSRS) score, and Alzheimer Disease’s Assessment Scale—cognitive subscale (ADAS-cog) score [131]. Here, INS is linked to Alzheimer disease.